These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32923126)

  • 1. A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.
    Casadesús AV; Deligne C; Diallo BK; Sosa K; Josseaume N; Mesa C; León K; Hernández T; Teillaud JL
    Oncoimmunology; 2020 Jun; 9(1):1770565. PubMed ID: 32923126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
    Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
    Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
    Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
    Front Immunol; 2022; 13():974188. PubMed ID: 36059465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.
    Abès R; Gélizé E; Fridman WH; Teillaud JL
    Blood; 2010 Aug; 116(6):926-34. PubMed ID: 20439625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD8
    Fiocca Vernengo F; Beccaria CG; Araujo Furlan CL; Tosello Boari J; Almada L; Gorosito Serrán M; Gazzoni Y; Montes CL; Acosta Rodríguez EV; Gruppi A
    mBio; 2020 May; 11(3):. PubMed ID: 32398312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
    Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
    Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
    Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
    Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Bhatt S; Parvin S; Zhang Y; Cho HM; Kunkalla K; Vega F; Timmerman JM; Shin SU; Rosenblatt JD; Lossos IS
    Blood; 2017 Apr; 129(16):2246-2256. PubMed ID: 28137826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
    J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-15 in the Combination Immunotherapy of Cancer.
    Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
    Front Immunol; 2020; 11():868. PubMed ID: 32508818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
    Wang J; Press OW; Lindgren CG; Greenberg P; Riddell S; Qian X; Laugen C; Raubitschek A; Forman SJ; Jensen MC
    Mol Ther; 2004 Apr; 9(4):577-86. PubMed ID: 15093188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice.
    Moritoki Y; Tsuneyama K; Nakamura Y; Kikuchi K; Shiota A; Ohsugi Y; Lian ZX; Zhang W; Yang GX; Ueki S; Takeda M; Omokawa A; Saga T; Saga A; Watanabe D; Miura M; Ueno Y; Leung PSC; Tanaka A; Gershwin ME; Hirokawa M
    Front Immunol; 2018; 9():2534. PubMed ID: 30450101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
    J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
    Nakamura K; Casey M; Oey H; Vari F; Stagg J; Gandhi MK; Smyth MJ
    Leukemia; 2020 Oct; 34(10):2708-2721. PubMed ID: 32269319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.
    Carmenate T; Pacios A; Enamorado M; Moreno E; Garcia-Martínez K; Fuente D; León K
    J Immunol; 2013 Jun; 190(12):6230-8. PubMed ID: 23677467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
    Wu Z; Xu Y
    J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.